TheraLase Technologies treats third patient with lead cancer compound

TheraLase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) told investors a third patient had been treated with its photo dynamic therapy (PDT) treatment for bladder cancer.

The procedure sees Theralase’s lead anti-cancer compound put through the urethra into the bladder.

The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water.

It is part of the Phase Ib NMIBC clinical study to evaluate the group’s lead cancer compound TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

The study is designed to treat three patients at a lower dose and to monitor them for 30 day. If deemed successful, a further six patients will be enrolled to be treated at a higher dose and be monitored for 180 days.

By the end of May , an independent Data and Safety Monitoring Board will recommend on whether to enroll six additional patients for PDT dose escalation.

Theralase chief Roger Dumoulin-White, said: “Theralase has now completed PDT treatment of the first 3 patients in the study and we look forward to successfully reporting out on our performance to the primary and secondary endpoints of the first three patients by the end of May 2017.”

Story by ProactiveInvestors